Philogen is a clinical-stage biotechnology company led by CEO Dr. Duccio Neri that focuses on antibody-based therapeutics. Its strategy is to deliver bioactive agents, such as cytokines or drugs, to sites of disease using antibodies and ligands that specifically target stromal antigens. The company currently has two products in Phase III development—Daromun for fully resectable Stage III B/C melanoma and Fibromun for metastatic soft tissue sarcoma—and additional candidates in Phase I and II. Philogen is fully integrated from discovery through GMP manufacturing and clinical trial execution and holds more than 40 international patent families. It maintains research activities at its subsidiary Philochem in Zürich, Switzerland, and has validating partnerships with big pharma. The company plans to use recent financing to progress pipeline products through clinical development and expand GMP facilities to enable large-scale production of antibody products.

Total raised

$70M

Funding rounds

1

Latest round

Equity

Latest activity

May 2019